SCHEMBL5368618

SCHEMBL5368618

O=C1Nc2c(Br)cc(Br)cc2C1=Cc1cc(Br)cc(Br)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.46
SIRT1 Q96EB6 3/20 0.45
MAP1LC3B Q9GZQ8 3/20 0.45
SIRT2 Q8IXJ6 2/20 0.45
SIRT3 Q9NTG7 2/20 0.45
RAF1 P04049 4/20 0.43
POLB P06746 2/20 0.42
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
KMT2A Q03164 3/20 0.40
LRRK2 Q5S007 3/20 0.40
BLM P54132 2/20 0.40
MEN1 O00255 2/20 0.40
PLK4 O00444 2/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363102 0.91 SIRT1 (0.46) ERN1SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL5366592 0.89 LRRK2 (0.48) SIRT1MAP1LC3BSIRT2SIRT3RAF1
SCHEMBL5366869 0.86 IGF1R (0.56) ERN1RAF1KMT2ALRRK2MEN1
SCHEMBL5365556 0.84 SIRT1 (0.46) ERN1SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL7136300 0.83 MAP3K7 (0.45) SIRT1MAP1LC3BSIRT2SIRT3RAF1
SCHEMBL5362718 0.82 MAP1LC3B (0.67) SIRT1MAP1LC3BSIRT2SIRT3RAF1
SCHEMBL5362880 0.82 PLK4 (0.57) SIRT1MAP1LC3BSIRT2SIRT3RAF1
SCHEMBL15577357 0.82 ERN1 (0.51) ERN1SIRT1MAP1LC3BSIRT2SIRT3
SCHEMBL7134818 0.82 MAP1LC3B (0.60) SIRT1MAP1LC3BSIRT2SIRT3RAF1
SCHEMBL5363330 0.81 MAP3K7 (0.43) SIRT1MAP1LC3BSIRT2SIRT3RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed
EP-0984930-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY Sugen, Inc. (US) 2000-03-15 EP disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERN1 1527/4885SIRT1 3834/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.